bis-N,N'-(2-hydroxy-4-nitrophenyl)-1,1'-biphenyl-4,4'-dicarboxamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: bis-N,N'-(2-hydroxy-4-nitrophenyl)-1,1'-biphenyl-4,4'-dicarboxamide
• 英文别名: N-(2-hydroxy-4-nitrophenyl)-4-[4-[(2-hydroxy-4-nitrophenyl)carbamoyl]phenyl]benzamide
• 化学式: C₂₆H₁₈N₄O₈
• 分子量: 514.451
• InChiKey: KXHJJGHETQKHMD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  38
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  190
• 氢给体数：
  4
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  4,4'-苯偶酰氯 、 2-氨基-5-硝基苯酚 在 三乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 18.0h， 以74%的产率得到bis-N,N'-(2-hydroxy-4-nitrophenyl)-1,1'-biphenyl-4,4'-dicarboxamide
  参考文献：
  名称：

  Synthesis of Analogues of Congo Red and Evaluation of Their Anti-Prion Activity

  摘要：

  No cure as of yet exists for any of the transmissible spongiform encephalopathies. In this paper, we describe the synthesis of analogues of Congo red and evaluation against a cellular model of infection, the SMB (scrapie mouse brain) persistently infected cell line, for their ability to inhibit the infectivity of the abnormal form of prion protein (PrP-res). The compounds have also been tested for their ability to inhibit the polymerization of PrPC by PrP-res. A number of analogues showed inhibition of PrP-res infectivity at nanomolar concentrations. Several analogues show promise; the most active compound, 2a, inhibits the formation of PrP-res in SMB cells with an EC50 of 25-50 nM.

  DOI：

  10.1021/jm049922t

文献信息

• Synthesis of Analogues of Congo Red and Evaluation of Their Anti-Prion Activity
  作者：Shane Sellarajah、Tamuna Lekishvili、Claire Bowring、Andrew R. Thompsett、Helene Rudyk、Christopher R. Birkett、David R. Brown、Ian H. Gilbert

  DOI：10.1021/jm049922t

  日期：2004.10.1

  No cure as of yet exists for any of the transmissible spongiform encephalopathies. In this paper, we describe the synthesis of analogues of Congo red and evaluation against a cellular model of infection, the SMB (scrapie mouse brain) persistently infected cell line, for their ability to inhibit the infectivity of the abnormal form of prion protein (PrP-res). The compounds have also been tested for their ability to inhibit the polymerization of PrPC by PrP-res. A number of analogues showed inhibition of PrP-res infectivity at nanomolar concentrations. Several analogues show promise; the most active compound, 2a, inhibits the formation of PrP-res in SMB cells with an EC50 of 25-50 nM.